

# 30 YEARS OF PROGRESS/CRYSTAL BALL: WHAT DOES THE FUTURE LOOK LIKE?

**Presented By: Thomas E. Serena, MD, FACS, FACHM MAPWCA**  
Founder & Chief Executive Officer SerenaGroup®  
President-elect - Association for the Advancement of Wound Care (AAWC)  
Board Member - American College of Hyperbaric Medicine  
Past President - American Professional Wound Care Association  
Faculty Angiogenesis Foundation  
Cambridge, MA

Spring SAWC 2017




**SerenaGroup**  
building the nation's leading wound care team.








# Diagnostics/Theranostics – Filling the Gap



# DIAGNOSTICS:





# POC Test #2: Bacterial Protease Activity (BPA)

Effectively identifying wounds that are in a **'period of pathogenicity™'** and are infected or are becoming infected and would benefit from appropriate intervention is clinically challenging.

The Chronic Wound Infection Continuum (adapted from ref. 2 & 3)

	Vigilance required		Intervention required	
Stages of chronic wound infection continuum	Not infected / Contamination	Period of Pathogenicity™	Local Infection Pathogenicity initiated (not observable)	Clear pathogenicity (observable infection)
	The presence of bacteria within a wound without host reaction	The presence of bacteria within the wound which do multiply or initiate host reaction	Multiplication of bacteria causing a delay in healing, usually associated with an exacerbation of pain not previously reported but still with no overt host reaction	The deposition and multiplication of bacteria in tissue with an associated host reaction


2. Wound Infection in Clinical Practice: An international consensus. *International Wound Journal* 2008; 5 (3): 1-11.

3. Collier M. Recognition and management of wound infections. *World Wide Wounds* 2004.

# INTERIM ANALYSIS OF A CLINICAL STUDY TO EVALUATE THE EFFECT OF BPA STATUS ON 12 WEEK HEALING RATE

n=[xxx] wounds at 7 US Wound Clinic trial sites. Includes pre-FDA clinical trial data plus [xx%] of completed 510(k) clinical trial data:

[48.6%] [(17/35)] of the wounds that reported WOUNDCHEK™ Bacterial Status\* negative tests had healed as opposed to only [22.4% (15/67)] of the wounds reporting positive WOUNDCHEK™ Bacterial Status\* tests.




**\*Product in Clinical Trial**

CONFIDENTIAL

# Bacterial Status in chronic wounds

## Development of Test:

Clinical research data to support test concept : BPA = bacterial protease activity





# CASE STUDY #1 – DIABETIC FOOT ULCER, RIGHT PLANTAR

## Week 0 :

- No clinical signs of infection
- **Positive for BPA**
- Treatment : Mepilex & Mepitel



## Week 4 :


- No clinical signs of infection
- **Positive for BPA**
- Treatment : Aquacel




## Week 5 :

- Patient bed ridden with chills and pains
- Foot swollen and increased odour
- Third digit is purple and 9x8cm area of redness on dorsal foot
- Patient referred to surgery for amputation

# DIAGNOSTICS IN HYPERBARIC MEDICINE



# STUDENT ATHLETES : TRAUMATIC BRAIN INJURY



# COOPERATIVE GROUP BOOK OF RCTS IN HBOT.

*Indocyanine Fluorescent Angiography (LUNA) vs Standard care for selecting patients with diabetic foot ulcers for hyperbaric oxygen therapy.*

HBOT vs standard wound care in patients with ischemic tissue loss after indirect revascularization.

HBOT pre and post surgery vs standard surgical intervention without HBOT in nipple sparing mastectomy procedures.


HBOT and SOC vs SOC in patients with interstitial cystitis.

HBOT in the treatment of patients with the erectile dysfunction secondary to late effects of radiation therapy.

HBOT in the treatment of Traumatic Brain Injury in Student Athletes

HBOT vs Standard of care in the Treatment of Patients with Autism Spectrum Disorder






## A NEW SOURCE OF AMNIOTIC MEMBRANE



# RESEARCH AROUND THE WORLD



Drawing



Mixing



Clotting



Placing



Dressing

# AUTOLOGOUS TISSUE





## NUTRITIONAL RESEARCH: ORAL AND PARENTERAL

### Provide sufficient calories

- 30 – 35 kcal/kg body weight for individuals under stress (e.g. pressure ulcers)
- More may be required if they are underweight.

### Provide adequate protein for positive nitrogen balance


- 1.25 – 1.5 grams protein/kg body weight
- Caution with renal insufficiency




# INTERACTIVE LEARNING SYSTEM: Wound Care Quality Measures

Measure Type	Domain	Measure Description
Process	Effective Clinical Care	Adequate Off-loading of DFU at Each Visit
Outcome	Effective Clinical Care	DFU Healing or Closure
Process	Effective Clinical Care	Comprehensive Diabetic Foot Examination
Process	Effective Clinical Care	Adequate Compression at Each Visit for Patients with VLU
Outcome	Effective Clinical Care	VLU Healing or Closure
Process	Care Coordination	Plan of Care for VLU not Achieving 30% Closure at 4 Weeks
Process	Effective Clinical Care	Appropriate Use of HBOT for Patients with DFU
Process	Effective Clinical Care	Appropriate Use of Cellular or Tissue Based Products for Patients Aged 18 Years or Older with a DFU or VLU
Process	Effective Clinical Care	Vascular Assessment of Patients with Chronic Leg Ulcers
Process	Effective Clinical Care	Wound Bed Preparation Through Debridement of Necrotic or Non-Viable Tissue
Outcome	Patient Engagement	Wound Related Quality of Life
Outcome	Effective Clinical Care	Hemoglobin A1c Poor Control
Process	Effective Clinical Care	Diabetic Foot and Ankle Care, Peripheral Neuropathy Evaluation
Process	Patient Safety	Documentation of Current Medications
Process	Community Population Health	Tobacco Use: Screening and Cessation Intervention


# TRANSLATIONAL RESEARCH: ONLY THE BEGINNING



# MECHANISM OF ACTION TRIALS: STEM CELLS



PERICYTES



EXOSOMES